Geovanna
Living with Recessive Dystrophic Epidermolysis Bullosa

Transforming Lives
Through the Promise of Genetic Medicine

CORPORATE OVERVIEW | 2H 2026

Abeona Therapeutics is a commercial-stage biopharmaceutical company that is dedicated to developing cell and gene therapies for severe and life-threatening diseases.

> Working together to deliver cell and gene therapies for people impacted by serious diseases.

Proven Expertise in Cell and Gene Therapy

Abeona is a fully integrated cell and gene therapy company that leverages its vast scientific research and drug development expertise to create, develop, manufacture and deliver life-changing genetic medicines. Led by an experienced management team with a track record of launching and commercializing novel therapies, including autologous gene therapies, both in the U.S. and globally, Abeona is well-positioned to advance efficacious and safe therapeutics that transform the lives of people impacted by devastating diseases.

Advancing and Commercializing Innovative Cell and Gene Therapies

At Abeona, we are working to commercialize differentiated therapies that redefine the standard of care for severe, life-threatening diseases.

At a Glance

HEADQUARTERS

Cleveland, OH

NASDAQ

ABEO

MANAGEMENT TEAM

Vishwas Seshadri, Ph.D., MBA
Chief Executive Officer, Director

Mohamad Tabrizi, MS, MBA
Chief Business Officer

Joseph Vazzano
Chief Financial Officer

Brendan O'Malley, J.D., Ph.D.
Chief Legal Officer

Gianine Esposito
Chief People Officer

Brian Kevany, Ph.D.
Chief Technical Officer and Chief Scientific Officer

Madhav Vasanthavada, Ph.D., MBA
Chief Commercial Officer

James Gow, MD, MBA, MS, MHCM
Senior Vice President, Clinical Development and Medical Affairs

Carl Denny
Senior Vice President, Regulatory Affairs

Greg Gin
Vice President, Investor Relations and Corporate Communications

Megan Callan
Vice President, Head of Quality

Amanda Moore, MSHS
Vice President, Program Leadership

ABEONA PROGRAMS



PARTNER PROGRAMS



*These are intended pivotal trials to support regulatory submission.

ZEVASKYN (prademagene zamikeracel)

To learn more, please visit ZEVASKYN.com.

PSMA SIR-T (ABO-701)

Metastatic prostate cancer remains a leading cause of cancer mortality, with more than 30,000 deaths annually in the U.S. despite multiple prior lines of therapy. PSMA SIR-T™, a first-in-class engineered autologous T-cell therapy, has demonstrated in preclinical studies durable tumor control, specificity to PSMA, and a modest cytokine release profile, a favorable safety signal absent in current cell therapy approaches. Its purpose-built SIR design is completely new, engineered to overcome the core failures of cell therapy. To learn more about SIR-T™ click here to watch a webinar from Preet Chaudhary, MD, Ph.D., professor of Medicine at Keck School of Medicine at USC.

UX111 | *Partnered with Ultragenyx*

AAV-based gene therapy for MPS IIIA: UX111 is a gene therapy for Sanfilippo syndrome type A (MPS IIIA), designed to correct SGSH enzyme deficiency. It targets the CNS to reduce heparan sulfate accumulation, aiming to slow neurodevelopmental and physical decline.

TSHA-102 | *Partnered with Taysha Gene Therapies*

AAV-based gene therapy for Rett syndrome: TSHA-102 delivers a functional copy of the MECP2 gene and features miRARE technology to regulate MECP2 expression cell-by-cell, minimizing the risk of overexpression in the CNS.

REV 2026JUN01